Compare iShares MSCI India ETF (INDA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Sanofi SA — how do they compare? iShares MSCI India ETF trades at $48.82, while Sanofi SA trades at $43.7 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares MSCI India ETF pays none, and iShares MSCI India ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| INDA | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $52.34 |
52-Week Low | $45.42 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $48.56, down 0.72% on the day, with neutral technical signals overall. The ETF shows bullish moving averages but neutral oscillators, with key support and resistance clustered around $49. Recent news highlights India's strong 7.8% GDP growth (CNBC, 2026-06-05) and ongoing comparisons with other India-focused ETFs amid foreign investor outflows.
The outlook remains mixed: India's robust economic expansion and strategic sector composition offer growth potential, but risks include geopolitical tensions, AI investment underperformance, and regulatory changes in clean energy. Analyst sentiment is cautiously optimistic, with some seeing value in INDA's discount to S&P 500 valuations.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
